Nafamostat and sepimostat identified as novel neuroprotective agents via NR2B N-methyl-D-aspartate receptor antagonism using a rat retinal excitotoxicity model

Fuwa M., Kageyama M., Ohashi K., Sasaoka M., Sato R., Tanaka M., Tashiro K.

2019
Scientific Reports

View publication

Therapeutic Area

Back of the eye (BOTE)
Categories

Preclinical development

Affiliations

Research and Development, Santen Pharmaceutical Co., Ltd, Nara, Japan; Global Alliances and External Research, Santen Pharmaceutical Co., Ltd, Nara, Japan; Department of Genomic Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto, Japan

Related Publications

Efficacy and Safety of Low-Concentration Atropine in Slowing Myopia Progression in Children in Japan: The Randomized, Double-Blind Phase II/III ORANGE Study

Ohno-Matsui K., Igarashi-Yokoi T., Migita Y., Yamakawa Y, on behalf of the ORANGE study investigators

Awareness of Myopia Associated Complications and Perspectives on Myopia Management Among Parents of Children with Myopia in France and the UK

Hafizi R., Deferne N., Paudel N., Angerer A., Hsieh H.-T.

Cutamesine (SA4503) Protects Retinal Ganglion Cells in an Ocular Hypertension Model of Glaucoma Determined Using Detection of Apoptosing Retinal Cells Technology and RBPMS Cell Marker

Sharif N.A., Takashi O., Taniguchi T., Sasaoka M., Guo L., Choi S., Luong V., Cordeiro M.F.

View all Back of the eye (BOTE) publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022